Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR mHealth and uHealth

Date Submitted: May 2, 2026
Open Peer Review Period: May 6, 2026 - Jul 1, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The Use of Therapeutic Conversational Agents (TCAs) for Depression Treatment in Cancer Patients: How to Guide Patients Who “Self-Prescribe” TCAs and Considerations for Potential Future Clinical Implementation

  • Abigail Laurel Blair; 
  • Amitabha Palmer

ABSTRACT

Depression is a common comorbidity among cancer patients that significantly worsens mortality, quality of life, and treatment adherence. Financial, geographic, and cultural barriers may limit access to conventional mental health care, and in response, many patients may self-prescribe digital mental health tools (DMHTs) without clinical guidance. Surveys indicate that roughly one in four Americans already uses large language models (LLMs) for mental health support, and this pattern almost certainly extends to cancer patients. LLM-based mental health chatbots fall under the broader category of therapeutic conversational agents (TCAs), which is the focus of this paper. This viewpoint argues that clinicians are in an analogous position to that of providers faced with unregulated dietary supplements: patients are using these tools regardless of physician endorsement, and they need informed clinical guidance. We first characterize the biological, psychological, and social dimensions of depression that are specific to cancer patients—including tumor type, disease stage, comorbidities, psychiatric history, personality factors, social support, and financial burden—and explain why these dimensions create heterogeneous risk profiles that must inform TCA deployment decisions. We then review current evidence on TCA capabilities and limitations. TCAs demonstrate efficacy for mild-to-moderate depression in short-course trials, and users form therapeutic bonds with them comparable to those formed with human therapists. However, critical limitations remain. TCAs fail to respond appropriately to simulated suicidality; are limited in cultural competence for non-Western and non-English-speaking populations; and may cause sycophancy-driven "delusional spiraling” among users. Drawing on this analysis, we offer ten clinical recommendations organized around technology assessment, depression severity, unhealthy use patterns, and future FDA-approved deployment. We recommend that TCAs serve only as adjuncts—never replacements—for patients with moderate-to-severe depression, high self-harm risk, or problematic technology use patterns. We also recommend that clinicians never delegate crisis monitoring to these tools. Finally, we argue that purely outcome-based frameworks for evaluating TCA integration risk undervaluing the intrinsic goods of human therapeutic relationships, particularly for cancer patients confronting isolation, existential distress, and mortality. Human-centered care ought to remain grounded in genuine vulnerability and reciprocity, and this approach should serve as the normative foundation guiding TCA adoption.


 Citation

Please cite as:

Blair AL, Palmer A

The Use of Therapeutic Conversational Agents (TCAs) for Depression Treatment in Cancer Patients: How to Guide Patients Who “Self-Prescribe” TCAs and Considerations for Potential Future Clinical Implementation

JMIR Preprints. 02/05/2026:98397

DOI: 10.2196/preprints.98397

URL: https://preprints.jmir.org/preprint/98397

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.